Manufacturer · 2026
Caliway Completes U.S. FDA IND Submission for SUPREME-02 Phase 3 Study of CBL-514
Caliway Biopharmaceuticals (2026). Caliway Completes U.S. FDA IND Submission for SUPREME-02 Phase 3 Study of CBL-514. Company press release.
Company press release
Last reviewed . By the PeptIQ team.
Peptides linked in PeptIQ Wiki
This page indexes a published source for discovery and cross-linking. PeptIQ reports what the literature contains and what users track — it does not interpret studies as treatment guidance.